This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Save the date!
November 6–8, 2023Munich, Germany

Scandion Oncology A/S - ONSITE PRESENTER


Scandion Oncology discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are world leaders in reverting the cancer’s resistance against treatment, thus making the treatment work better and longer thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.

Globally, close to 10 mio patients die every year from treatment resistant cancers, and our medicines are relevant in several different cancers. This gives us the potential to provide treatment to millions of people, who today don’t have effective treatment options.

We focus on clinical development of our most promising compounds to achieve proof of concept and confirmation hereof in pivotal trials. We fund our pipeline-investments through various sources, including capital raises, with the aim of ensuring maximum long term value creation for patients, investors, and society.

Scandion Oncology is listed on Nasdaq First North Growth Market Sweden (SCOL).

Company Website

We're bringing you

  • Company Presentations